Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Alimera Sciences’

Alimera Sciences: Will The Launch of Iluvien Be Disappointing to Investors? (ALIM, Neutral, $5.53)

Investment Issues The investment outlook for Alimera (ALIM) is completely dependent on the commercialization of Iluvien, an ophthalmic implant for the treatment of diabetic macular edema (DME); there is no pipeline. Alimera licensed this product from pSivida (PSDV) and is commercializing it on a worldwide basis. The product has been launched in Germany, the UK […]

pSivida: Previewing the October 17th PDUFA Date for Iluvien (PSDV, $5.07)

Investment Scenarios: The Positive and Negative Case pSivida (PSDV) has a very important binary event upcoming on October 17, 2013; this is the PDUFA date for Iluvien, an ocular implant for diabetic macular edema that was licensed to Alimera (ALIM). I cannot answer the question of whether the government shutdown might delay the PDUFA date […]